Specialties
National Distinction in Structural Heart Care
As one of the country’s busiest and most active structural heart programs, we have established a national benchmark in structural heart care by embracing leading-edge procedures and an enterprise-wide collaborative model.
2026 Outcomes
By embracing next-generation valve technologies and innovative treatments, we have become a leader in structural heart care. Our collaborative, enterprise-wide model enables us to deliver comprehensive, personalized care for all four heart valves—aortic, mitral, tricuspid and pulmonary—ensuring exceptional patient outcomes and upholding our commitment to clinical excellence.
Complex heart valve disease care
Leading innovation in aortic insufficiency care
As the only program in Dallas-Fort Worth and one of just two in Texas participating in JenaValve therapies for aortic regurgitation, our team provides access to both the commercial JenaValve platform and the ARTIST AR clinical study, helping bring next-generation transcatheter treatment options to patients with limited alternatives.
Pioneering novel treatments for mitral stenosis due to mitral annular calcification (MAC) and rheumatic valve disease
Our structural heart team performs IVL-assisted balloon mitral valvuloplasty and mitral valve-in-MAC (ViMAC), bringing innovative transcatheter solutions to patients with some of the most complex forms of mitral valve disease.
Full-spectrum surgical backup and revision
Our commitment to patient care spans the entire structural heart lifecycle. For complex patients who previously received transcatheter therapies elsewhere, our surgical heart team delivers expert surgical explantation and total valve replacement for degenerated or failed prostheses.
clinical firsts
First commercial Edwards Lifesciences Sapien M3
transcatheter mitral replacement devices
First TriClip G5 TEER implants
for edge-to-edge tricuspid valve repair
TAVR Volumes
PLANO AND DALLAS
The highest performing TAVR programs in the country with 13%+ growth over the last year
37 ACTIVE CLINICAL TRIALS
COMPREHENSIVE CIED THERAPIES
Turning ‘no-option’ patients into success stories: Advanced catheter electrosurgery
Our heart team uses radiofrequency-energized guidewires in vivo to modify native and prosthetic heart tissues, preventing lethal coronary or outflow obstructions during valve replacement—and offering an option for complex patients who cannot receive standard transcatheter therapies.
Academic leadership
Our physicians provided education through over 50 live cases broadcast globally
- CITIC (Mexico City, Mexico): M-TEER procedures
- Beijing Valves (Beijing, China): Transcatheter mitral valve-in-ring with electrosurgery
- ACVS India: Transcatheter aortic regurgitation intervention procedures
Quality Awards 2026
Ranked among the nation's elite
Heart & Vascular Surgery
